Next Article in Journal
Presence of Babesia odocoilei and Borrelia burgdorferi Sensu Stricto in a Tick and Dual Parasitism of Amblyomma inornatum and Ixodes scapularis on a Bird in Canada
Previous Article in Journal
Attitudes of Doctors and Nurses toward Patient Safety within Emergency Departments of a Saudi Arabian Hospital: A Qualitative Study
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessArticle

Adverse Event Circumstances and the Case of Drug Interactions

Molecular Health GmbH, Kurfuersten Anlage 21, 69115 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Healthcare 2019, 7(1), 45; https://doi.org/10.3390/healthcare7010045
Received: 15 February 2019 / Revised: 15 March 2019 / Accepted: 18 March 2019 / Published: 19 March 2019
  |  
PDF [851 KB, uploaded 25 March 2019]
  |  

Abstract

Adverse events are a common and for the most part unavoidable consequence of therapeutic intervention. Nevertheless, available tomes of such data now provide us with an invaluable opportunity to study the relationship between human phenotype and drug-induced protein perturbations within a patient system. Deciphering the molecular basis of such adverse responses is not only paramount to the development of safer drugs but also presents a unique opportunity to dissect disease systems in search of novel response biomarkers, drug targets, and efficacious combination therapies. Inspired by the potential applications of this approach, we first examined adverse event circumstances reported in FAERS and then performed a molecular level interrogation of cancer patient adverse events to investigate the prevalence of drug-drug interactions in the context of patient responses. We discuss avoidable and/or preventable cases and how molecular analytics can help optimize therapeutic use of co-medications. While up to one out of three adverse events in this dataset might be explicable by iatrogenic, patient, and product/device related factors, almost half of the patients in FAERS received multiple drugs and one in four may have experienced effects attributable to drug interactions. View Full-Text
Keywords: adverse events; drug-drug interactions; health informatics; outcome analytics; molecular mechanism based safety assessment; real world data; public health adverse events; drug-drug interactions; health informatics; outcome analytics; molecular mechanism based safety assessment; real world data; public health
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Soldatos, T.G.; Jackson, D.B. Adverse Event Circumstances and the Case of Drug Interactions. Healthcare 2019, 7, 45.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Healthcare EISSN 2227-9032 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top